<DOC>
	<DOCNO>NCT02024295</DOCNO>
	<brief_summary>To determine efficacy safety S-adenosyl-l-methionine alcoholic hepatitis cholestasis .</brief_summary>
	<brief_title>Efficacy Safety S-adenosyl-l-methionine Treatment Alcoholic Hepatitis With Cholestasis</brief_title>
	<detailed_description>randomize first time core treatment stage 6 week , randomize second time extend treatment 42 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Polyene phosphatidylcholine</mesh_term>
	<criteria>Body Mass Index range 1930kg/m2 Alcohol Drinking history 5 year , male ≥ 40g/ day , female ≥ 20g/ day ; STB 2 10X ULN ; ALP &gt; 1.5X ULN GGT &gt; 3X ULN one , active virus hepatitis , antiHIV ( + ) exclude hepatic disease : nonalcoholic fatty liver , druginduced liver injury , autoimmune hepatitis ( AMA/ANA &gt; 1:100 ) , Wilson disease , hemochromatosis hepatic disease ; obstructive cholestasis nonhepatic disease cause jaundice primary hepatic carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>